Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 33211441!ä!33211441 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Med+Liege 2020 ; 75 (S1): 162-169 Nephropedia Template TP {{tp|p=33211441|t=2020. Le point sur les strategies medicamenteuses contre la COVID-19 : entre espoirs et deceptions |pdf=|usr=}}{{33211441}} gab.com Text Le point sur les strategies medicamenteuses contre la COVID-19 : entre espoirs et deceptions JO: Rev Med Liege http://www.kidney.de/pget.php?&tw=1&pmid=33211441 #FOAvip The COVID-19 outbreak has raised numerous attempts of diverse pharmacological interventions to improve the prognosis of the infection, especially among hospitalized patients due to an acute respiratory distress syndrome (ARDS). Initially, these interventions used known medications capable to directly target SARS-CoV-2 by investigating several antiviral therapies already applied with some success in other viral infections. Among them remdesivir appears to be the most promising drug against SARS-CoV-2. Then, owing to the deleterious impact of the cytokine storm, medications that more specifically inhibit proinflammatory cytokines (especially interleukin-1 and interleukin-6) were tested. Hydroxychloroquine, sometines combined with azithromycin, has benefited for a while from a media buzz. However, hopes initially founded in all such drugs turned into disappointments because the specificities of SARS-CoV-2 make this virus resistant to most pharmacological interventions. Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects. These corticosteroids are currently recommended by the World Health Organisation. An intensive research is ongoing worldwide to find effective combined therapies or innovative drugs which could unequivocally improve the prognosis of COVID-19 at the different stages of the infection. Twit Text FOAVip Le point sur les strategies medicamenteuses contre la COVID-19 : entre espoirs et deceptions ????Rev Med Liege http://www.kidney.de/pget.php?&tw=1&pmid=33211441 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33211441 #FOAvip English Wikipedia <ref>{{Cite pmid|33211441}}</ref> Le point sur les strategies medicamenteuses contre la COVID-19 : entre espoirs et deceptions #MMPMID33211441 Scheen AJ; Moutschen M Rev Med Liege 2020[Sup]; 75 (S1): 162-169 PMID33211441show ga The COVID-19 outbreak has raised numerous attempts of diverse pharmacological interventions to improve the prognosis of the infection, especially among hospitalized patients due to an acute respiratory distress syndrome (ARDS). Initially, these interventions used known medications capable to directly target SARS-CoV-2 by investigating several antiviral therapies already applied with some success in other viral infections. Among them remdesivir appears to be the most promising drug against SARS-CoV-2. Then, owing to the deleterious impact of the cytokine storm, medications that more specifically inhibit proinflammatory cytokines (especially interleukin-1 and interleukin-6) were tested. Hydroxychloroquine, sometines combined with azithromycin, has benefited for a while from a media buzz. However, hopes initially founded in all such drugs turned into disappointments because the specificities of SARS-CoV-2 make this virus resistant to most pharmacological interventions. Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects. These corticosteroids are currently recommended by the World Health Organisation. An intensive research is ongoing worldwide to find effective combined therapies or innovative drugs which could unequivocally improve the prognosis of COVID-19 at the different stages of the infection. |*Antiviral Agents/therapeutic use[MESH] |*Betacoronavirus[MESH] |*Coronavirus Infections/drug therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Humans[MESH]Le point sur les strategies medicamenteuses contre la COVID-19 : entre(epmc).pdf DeepDyve Pubget Overpricing